← History of this study ↑ Current version of this study

View of NCT00849654 on 2009_02_23

This study has duplicate: NCT01177878

ClinicalTrials Identifier: NCT00849654
Updated: 2009_02_23

Descriptive Information

Brief title	Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Official title	Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma

Brief summary

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.

Detailed description

Phase	Phase 1
Study type	Interventional
Study design	Treatment
Study design	Non-Randomized
Study design	Open Label
Study design	Uncontrolled
Study design	Single Group Assignment
Study design	Safety Study
Primary outcome	Measure: Dose limiting toxicity assessment for each patient. Time Frame: At the end of the first 35 day cycle Safety Issue? Yes
Primary outcome	Measure: Adverse events Time Frame: 30 days after last dose of study drug Safety Issue? Yes
Primary outcome	Measure: Pharmacokinetic/ Pharmacodynamic assessments Time Frame: during Cycle 1 Safety Issue? No
Secondary outcome	Measure: Tumor response Time Frame: at the end of Cycles 2, 4, and 6 Safety Issue? No
Enrollment	36 (Anticipated)
Condition	B-Cell Lymphoma

Condition	B-Cell Leukemia
Condition	Bruton's Tyrosine Kinase
Arm/Group	Arm Label: PCI-32765 Experimental
Intervention	Drug: PCI-32765 Arm Label: PCI-32765 PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose cohorts orally once per day for 28 days followed by a 7 day rest period. Six patients will be enrolled in each dosing cohort. If ≥ 2 DLTs occur in any cohort, the MTD will be established as the previous dosing cohort. If MTD is not reached, dosing levels may be increased beyond 17.5 mg/kg/d by 33% increments. The study will continue until the MTD has been established. Patients who do not experience DLT during Cycle 1 may continue with additional cycles of 28 day PCI-32765 treatment followed by a 7 day rest period for a maximum of six cycles provided that there is no disease progression or DLT.
URL	http://www.pharmacyclics.com
See also	

Recruitment Information

Status	Recruiting
Start date	2009-02
Primary completion date	2010-02 (Anticipated)

Criteria

Inclusion Criteria:
• Women and men ≥ 18 years of age. There is no experience with this drug in a pediatric population.
• Body weight ≥ 40 kg.
• Recurrent surface immunoglobulin positive B cell non-Hodgkin's lymphoma (according to WHO classification) including small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL).
• Bi-dimensional measurable disease (≥ 2 cm diameter or for CLL ≥ 4000 leukemia cells/mm3).
• Have failed ≥ 1 previous treatment for lymphoma and no standard therapy is available. Patients with diffuse large B cell lymphoma must have failed, refused or be ineligible for autologous stem cell transplant.
• ECOG performance status of ≤ 1.
• Ability to swallow oral capsules without difficulty.
• Willing and able to sign a written informed consent.

Exclusion Criteria:
- More than four prior systemic therapies (not counting maintenance rituximab).

Salvage therapy/conditioning regimen leading up to autologous bone marrow transplantation is considered to be one regimen.
• Prior allogeneic bone marrow transplant.
• Immunotherapy, chemotherapy, radiotherapy or experimental therapy within 4 weeks before first day of study drug dosing.
• Major surgery within 4 weeks before first day of study drug dosing.
• CNS involvement by lymphoma.
• Active opportunistic infection or treatment for opportunistic infection within 4 weeks before first day of study drug dosing.
• History of malabsorption.
• Laboratory abnormalities:
• Creatinine > 1.5 × institutional upper limit of normal (ULN)
• Total bilirubin > 1.5 x institutional ULN (unless elevated from documented Gilbert's syndrome)
• AST or ALT > 2.5 × institutional ULN
• Platelet count < 75,000/μL
• Absolute neutrophil count (ANC) < 1500/μL.
• Uncontrolled illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart failure), unstable angina pectoris, cardiac arrhythmia, and psychiatric illness that would limit compliance with study requirements.
• Risk factors for, or use of medications known to prolong QTc interval or that may be associated with Torsades de Pointes within 7 days of treatment start (see Appendix C).
• QTc prolongation (defined as a QTc ≥ 450 msecs) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min). If the screening ECG has a QTc ≥ 450 msecs, the ECG can be submitted for a centralized, cardiologic evaluation.
• History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or stenting within the past 6 months.
• Known HIV infection.
• Other medical or psychiatric illness or organ dysfunction which, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the study agent.
• Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound).
• Women of child-bearing potential or sexually active men, unwilling to use adequate contraceptive protection during the course of the study.
• History of prior cancer < 5 years ago, except for basal cell or squamous cell carcinoma of the skin, cervical cancer in situ or other in situ carcinomas.

Gender	Both
Minimum age	18 Years
Healthy volunteers	No

Administrative Data

Organization name	Pharmacyclics

Organization study ID	PCYC-04753
Sponsor	Pharmacyclics
Health Authority	United States: Food and Drug Administration